Please Wait
Applying Filters...
menu
    • menu
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Tegavivint

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Iterion Validates Tegavivint in Advanced HCC at ASCO
    Iterion Validates Tegavivint in Advanced HCC at ASCO

    01 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-reports-first-clinical-validation-of-tegavivint-as-a-targeted-therapy-for-wnt-driven-advanced-hcc-in-oral-presentation-at-2026-asco-annual-meeting-302786514.html

    PR NEWSWIRE
    01 Jun 2026
    Share Share
    Iterion to Present Tegavivint HCC Carcinoma Data at ASCO 2026
    Iterion to Present Tegavivint HCC Carcinoma Data at ASCO 2026

    04 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-oral-presentation-of-phase-12-tegavivint-data-in-advanced-hepatocellular-carcinoma-at-the-2026-asco-annual-meeting-302761016.html

    PR NEWSWIRE
    04 May 2026
    Share Share
    Iterion Unveils Tegavivint Data For Wnt-Driven Cancers At AACR
    Iterion Unveils Tegavivint Data For Wnt-Driven Cancers At AACR

    13 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-presents-new-data-on-first-in-class-tbl1-inhibitor-tegavivint-targeting-wnt-driven-cancers-at-aacr-annual-meeting-302737103.html

    PR NEWSWIRE
    13 Apr 2026
    Share Share
    Iterion Therapeutics Expands Clinical Development of Tegavivint
    Iterion Therapeutics Expands Clinical Development of Tegavivint

    25 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-expands-clinical-development-of-tegavivint-a-first-in-class-wnt-catenin-inhibitor-into-colorectal-cancer-with-first-patient-dosed-302724330.html

    PR NEWSWIRE
    25 Mar 2026
    Share Share
    Iterion Launches Tegavivint Trial in Relapsed Osteosarcoma
    Iterion Launches Tegavivint Trial in Relapsed Osteosarcoma

    10 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-clinical-study-of-tegavivint-a-first-in-class-wnt-catenin-inhibitor-in-relapsedrefractory-osteosarcoma-302683289.html

    PR NEWSWIRE
    10 Feb 2026
    Share Share
    Iterion Announces First Patient Dosed in Phase 1b/2a Trial of Tegavivint
    Iterion Announces First Patient Dosed in Phase 1b/2a Trial of Tegavivint

    20 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-tegavivint-in-patients-with-advanced-hepatocellular-carcinoma-who-have-failed-one-or-more-systemic-treatments-302065477.html

    PR NEWSWIRE
    20 Feb 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.